Jan 27 2024

Arizona Marijuana Workers Vote Overwhelmingly to Unionize

Employees at a marijuana cultivation facility in Arizona voted this week to unionize, with 90% of workers in support of the move.

On Thursday workers at the Trulieve Cannabis Corp central Phoenix production facility voted 37 to 4 in favor of unionizing with the United Food and Commercial Workers Union (UFCW) Local 99.

“The successful union election at Trulieve Magnolia is the first for Arizona agricultural workers in the cannabis industry, and only the second-ever union election to be administered by the Arizona Agricultural Labor Relations Board (AERB)”, states a UFCW press release. “Established in 1993, the AERB’s statutes are patterned after the National Labor Relations Act, which specifically excludes agricultural workers from its jurisdiction.”
Continue reading

Jan 27 2024

Marijuana Stock Index Up 30% From 90 Days Ago

The Global Cannabis Stock Index has seen a significant increase over the past 90 days.

At the time of publication the Global Cannabis Stock Index stands at 9.06. This marks a 30.7% increase over where the market stood 90 days ago, when it was at 6.93. The high point over the past 30 days came on Thursday, January 25, with the market at 9.13.

The slow but steady increase over the past few moths may be related to the fact that the US Department of Health and Human Services (HHS) recently confirmed that they’re in talks with the Drug Enforcement Administration (DEA) regarding the potential rescheduling of marijuana. HHS is recommending that marijuana be moved to Schedule III, a move that would legalize medical marijuana for prescription use across the United States.
Continue reading

Jan 26 2024

Poll: Majority of Likely Voters in All 50 States Support Legalizing Marijuana, Nationwide Support at 57%

According to newly released polling, a strong majority of likely voters int he United States, including a majority in all 50 states, support legalizing recreational marijuana.

For the Politics and Advocacy Poll, conducted by The Tarrance Group, participants were asked:

“As you may know, most states have legalized marijuana for medical use, recreational use or both.
But currently all uses of marijuana are illegal at the federal level. Do you favor or oppose legalization
of marijuana by the U.S. government, which would legalize it in all 50 states?”
Continue reading

Jan 26 2024

Virginia Subcommittee Advances Bill to Legalize Recreational Marijuana Sales

Despite legalizing recreational marijuana in 2024, Virginia remains the only legal marijuana state to not allow sales in any capacity. A bill making its way through the state’s legislature could change that.

Yesterday a Senate subcommittee voted to advance Senate Bill 423, which would establish a licensed and regulated market for legal marijuana.

Under the proposed law, which must be approved through several more committees before it can be considered by the full Senate, the state would license up to 400 marijuana stores starting in 2025.
Continue reading

Jan 26 2024

Federal Legislation to Allow Marijuana Banking Gains 99th Sponsor in US House

The SAFE Banking Act gained its 99th sponsor yesterday in the United States House of Representatives.

The SAFE Banking Act would provide federal protections to banks and other financial services such as credit unions that provide services to marijuana businesses that are legal under their state’s law. This includes debit card services, businesses loans and other banking services.

The proposal was filed in April with eight cosponsors. Yesterday, Representative Derrick Van Orden (R-WI) became the 99th person to sponsor the bill, and the 91st since its filing.
Continue reading

Jan 25 2024

New Hampshire Committee Approves Bill to Allow Physicians to Recommend Medical Marijuana for Any Condition

A New Hampshire legislative committee has given approval to a bill that would greatly expand the number of people eligible to become a medical marijuana patient.

Filed by State Representative Wendy Thomas along with five cosponsors, House Bill 1278 was approved today in a unanimous 20 to 0 vote by the House Health, Human Services and Elderly Affairs Committee.

The proposed law would repeal the state’s list of qualifying medical marijuana conditions and would replace it with a provision stating that “For adults 21 years of age or older, any debilitating or terminal medical condition or symptom for which the potential benefits of using therapeutic cannabis would, in the provider’s clinical opinion, likely outweigh the potential health risks for the patient.”
Continue reading

Jan 25 2024

US Senate and House Bills Filed to Allow State-Legal Marijuana Use at Public Housing

Legislation that would allow those in public housing to use marijuana without fear of eviction if they are following state law has been refiled in the United States Senate and House of Representatives.

(Photo credit: Getty Images).

Congressmember Eleanor Holmes Norton (D-DC) and Senator Cory Booker (D-NJ) introduced the Marijuana in Federally Assisted Housing Parity Act today to permit the use of marijuana in federally assisted housing, including public housing and Section 8 housing, in compliance with the marijuana laws of the state (including the District of Columbia) where the property is located. Under current federal law, users of drugs that are illegal under federal law, including marijuana, are prohibited from being admitted into federally assisted housing.

Federal law also allows landlords to evict residents of federally assisted housing for illegal drug use. Adult-use marijuana, medical marijuana or both are currently legal in D.C., New Jersey and 37 other states, and over 90 percent of Americans support legalized medical marijuana.
Continue reading

Jan 25 2024

Delaware House Passes Bill to Enhance Patient Access to Medical Marijuana

Delaware’s full House of Representatives passed legislation on Thursday that would enhance patient access to medical marijuana, including allowing physicians to recommend the medicine for any condition they deem appropriate.

Sponsored by State Representative Ed Osienski, House Bill 285 would make several changes to the way medical marijuana cards are issued, and it removes barriers that prevent patients from accessing medical marijuana in Delaware.

“Following our successful passage of the Delaware Marijuana Control Act last year, establishing a framework for the legalization and regulation of recreational marijuana use in our state, we have actively engaged with and taken feedback from medical marijuana patients. Drawing from their insights, we identified numerous ways to improve our medical marijuana program,” said Rep. Ed Osienski.
Continue reading

Jan 25 2024

South Dakota Lawmakers Reject Bill to Limit Access to Medical Marijuana

Lawmakers in South Dakota voted to reject legislation that would have made it harder to become a medical marijuana patient.

The Senate Health and Human Services Committee voted 5 to 2 yesterday to defer any action on Senate Bill 82. The measure was filed last week by Senator Jim Mehlhaff along with 14 cosponsors.

The proposed law would have forced those seeking a medical marijuana authorization to obtain it exclusively through their primary care physician or a healthcare provider recommended by their primary physician. The legislation would have imposed criminal penalties on doctors who recommended medical marijuana to someone who they are not a primary physician for.
Continue reading

Jan 25 2024

Study: Psilocybin Could Be “Revolutionary in Treating Depression” and Become Alternative to SSRIs

Psilocybin mushrooms “could prove to be revolutionary in treating depression and become an alternative medication to SSRI”, finds a new study.

Titled Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults – A Systematic Review, the study was published in the journal Clinical Psychopharmacology and Neuroscience. The study was conducted by researchers at Keele University in the United Kingdom.

“Psilocybin is a classical psychedelic which has been utilised for healing purposes for millenia”, notes the study. “However, with its classification as a Schedule I substance, research into this compound is scarce with few FDA-approved clinical studies.”
Continue reading